 New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension PAH patients demonstrate positive trends in exploratory endpoints, including quality of life QoLRESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 GLOBE NEWSWIRE -- Liquidia Technologies, Inc. NASDAQ: LQDA, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology, announced that exploratory endpoint data from the INSPIRE study evaluating LIQ861 in patients with pulmonary arterial hypertension PAH was released today through a virtual presentation at the American Thoracic Society ATS Annual Meeting. LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed and engineered using Liquidias novel PRINT technology with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler.The data from the INSPIRE study were made available via a prerecorded poster session and showed results from standard measures used to evaluate clinical symptoms and functional ability, which were exploratory endpoints and not subject to formal statistical analysis. Overall, improvements from baseline following treatment with LIQ861 for two months included an increase in six-minute walk distance 6MWD; clinically meaningful reduction improvement in the Minnesota LIVING WITH HEART FAILURE Questionnaire MLHFQ total score; lower improved New York Heart Association functional class NYHA FC status; and the percentage of subjects who met two or three PAH low-risk criteria increased from baseline.We are very pleased with the results of LIQ861 on these exploratory endpoints and believe these findings warrant further evaluation in this difficult to treat patient population, said Nicholas Hill, MD, Chief Pulmonary, Critical Care Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator. Previously reported primary endpoints from the INSPIRE study support the safety and tolerability profile of LIQ861 and a continuation of positive trends seen in these exploratory endpoints will only reinforce its potential as a viable treatment option, if approved, for patients with PAH.INSPIRE, a phase 3, open-label, multicenter study of two World Health Organization WHO Group 1 pulmonary arterial hypertension PAH patient cohorts, enrolled a total of 121 patients. The first patient group included stable PAH patients on 2 non-prostacyclin PAH therapies add-on and the second group included subjects who transitioned from treatment with Tyvaso treprostinil transition.The initial dose for transition patients n55 was based on their Tyvaso dose at the time of transition and the starting dose for add-on patients n66 was 26.5 mcg QID. Titration to a higher LIQ861 dose was permitted in both groups based on symptom relief at the discretion of the physicians.Results of the exploratory endpoints evaluated in the INSPIRE study showed: More than 70 percent of patients were able to titrate to a LIQ861 dose 79.5 mcg. NYHA functional class improved in 20.5 percent of patients and maintained in 75.9 percent. Overall median 6MWD increased by 10.1 m. There was no clinically meaningful change in NT-proBNP. MLHFQ showed an improved total score 5-point reduction, as well as in both emotional and physical dimensions. A larger percentage of patients met two-or-three PAH low-risk criteria at month 2 compared with baseline. The majority of transition patients preferred the LIQ861 dry-powder inhaler to the Tyvaso Inhalation System.The PAH community has substantial unmet needs, like so many others with rare disease, said Tushar Shah, M.D., Chief Medical Officer of Liquidia. By leveraging our propriety PRINT technology, we were able to develop a convenient, dry powder inhaler that delivers the required dose of highly uniform treprostinil particles in one-to-two breaths. If approved, we believe that the LIQ861 dry powder inhaler could offer PAH patients a much-needed alternative treatment option and we are deeply committed to delivering such options to the PAH community.The INSPIRE study safety and tolerability outcomes at month 2 were recently presented at the International Society for Heart Lung Transplantation ISHLT Annual Meeting. Furthermore, Liquidia submitted the New Drug Application NDA for LIQ861 to the U.S. Food and Drug Administration FDA under the 505b2 regulatory pathway, which includes data from three clinical studies establishing the safety, tolerability and pharmacokinetic profile of LIQ861. On April 8, 2020, Liquidia announced the FDA had accepted the NDA for review and that it had been provided a Prescription Drug User Fee Act PDUFA goal date of November 24, 2020.About INSPIRE Clinical Trial Liquidias pivotal open-label phase 3 clinical trial, known as INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, was designed to evaluate patients who have either been under stable treatment with nebulizer-delivered treprostinil for at least three months and are transitioned to LIQ861 under the protocol or patients who have been under stable treatment with no more than two non-prostacyclin oral PAH therapies for at least three months and have their treatment regimen supplemented with LIQ861 under the protocol.The primary objective of the INSPIRE study was to evaluate the long-term safety and tolerability of LIQ861 and was observed to be well-tolerated in 121 patients, with 113 patients 93 percent completing their two-month visit. During that period, LIQ861 was evaluated at doses ranging from 26.5 mcg to 159 mcg with no study-drug related serious adverse events observed. Reported treatment-emergent adverse events TEAEs were mostly mild to moderate in nature, the most common reported in 4 percent being cough 42 percent, headache 26 percent, throat irritation 16 percent, dizziness 11 percent, diarrhea 9 percent, chest discomfort 8 percent, nausea 7 percent, dyspnea 5 percent, flushing 5 percent and oropharyngeal pain 4 percent.For more information, please visit PAH PAH is a chronic, progressive disease caused by the hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Treprostinil is a synthetic analog of prostacyclin, a vasoactive mediator essential to normal lung function that is deficient in patients with PAH. PAH is a rare disease, with an estimated prevalence in the United States of approximately 30,000 patients. The exact cause of PAH is often unknown and, although the symptoms are treatable, there is no known cure for the disease.About Liquidia Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension PAH and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit Cautionary Statements Regarding Forward-Looking StatementsThis press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs, regulatory applications and related timelines, including potential U.S. Food and Drug Administration FDA approval of the New Drug Application NDA for LIQ861, the timeline or outcome related to our patent litigation pending in the U.S. District Court for the District of Delaware or two petitions for inter partes review with the Patent Trial and Appeal Board, and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, would, and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. 